GLP-1 Trial Maintains Motor Function in Parkinson’s Disease

Citation: Athauda D et al., 2025, New England Journal of Medicine, DOI 10.1056/NEJMoa2306791
Research Summary:
A randomized double-blind Phase 2 trial evaluated lixisenatide, a GLP-1 receptor agonist, in 156 individuals Participants received lixisenatide or placebo over 12 months. The lixisenatide group maintained stable with a decline in the placebo group. Gastrointestinal effects were the most common adverse events. Motor after treatment ended.
Clinical Implications:
Findings suggest that GLP-1 agonists may slow neurodegeneration beyond symptomatic relief. For rural the potential for metabolic-pathway therapies to preserve motor function with manageable side effects.
Keywords: parkinsons, glp-1, neuroprotection, lixisenatide, clinical-trial